EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Pharmacokinetics and Pharmacodynamics of Ximelagatran

Michael Wolzt, Troy S Sarich, Ulf G Eriksson

Seminars in Vascular Medicine · 01.01.2005 · 5 (03) · 245-253

DOI: 10.1055/s-2005-916163 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Seminars in Vascular Medicine, erschienen am 01.01.2005. Verfasst von Michael Wolzt und 2 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, Allgemeines Krankenhaus Wien, Waehringer Guertel 18-20, Medical University of Vienna, Vienna, Austria. Die Arbeit wurde bisher 4-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oral anticoagulant therapy with vitamin K antagonists (VKAs) such as warfarin has proven benefits in the treatment and prevention of thromboembolic disorders but has important limitations that result in substantial underuse. In particular, the VKAs have variable and unpredictable pharmacokinetics and pharmacodynamics and a narrow separation between antithrombotic and hemorrhagic effects that necessitates careful dose adjustment based on frequent coagulation monitoring. In contrast, the oral direct thrombin inhibitor ximelagatran has a predictable and reproducible pharmacokinetic/pharmacodynamic profile that allows treatment using fixed-dose regimens without coagulation monitoring. The bioavailability of melagatran, the active form of ximelagatran, after oral administration of ximelagatran is ∼20% with low inter- and intra-individual variability. Peak plasma melagatran concentrations are reached ∼2 hours after oral dosing of ximelagatran to healthy volunteers, and melagatran is eliminated with a half-life of ∼3 hours with clearance predominantly by renal excretion. Hence, a higher melagatran exposure is seen in patients with renal failure; ximelagatran is currently not recommended for patients with severe renal impairment (creatinine clearance of

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Administration, OralAnticoagulantsAzetidinesBenzylaminesBiological AvailabilityGlycineHumansThrombin

Substanzen

AnticoagulantsAzetidinesBenzylaminesmelagatranximelagatranThrombinGlycine

Autor:innen und Institutionen

  • Clinical Pharmacology, Allgemeines Krankenhaus Wien, Waehringer Guertel 18-20, Medical University of Vienna, Vienna, Austria.

Zitieren

APA

Wolzt, M., Sarich, T. S., & Eriksson, U. G. (2005). Pharmacokinetics and Pharmacodynamics of Ximelagatran. Seminars in Vascular Medicine, 5(03), 245-253. https://doi.org/10.1055/s-2005-916163

Vancouver

Wolzt M, Sarich TS, Eriksson UG. Pharmacokinetics and Pharmacodynamics of Ximelagatran. Seminars in Vascular Medicine. 2005;5(03):245-253. doi:10.1055/s-2005-916163

BibTeX
@article{Wolzt2005,
  author = {Wolzt, Michael and Sarich, Troy S and Eriksson, Ulf G},
  title = {Pharmacokinetics and Pharmacodynamics of Ximelagatran},
  journal = {Seminars in Vascular Medicine},
  year = {2005},
  volume = {5},
  number = {03},
  pages = {245--253},
  doi = {10.1055/s-2005-916163}
}
Kostenlos starten →